So-called "superficial" bladder tumors. Which classification in 2003? Part 2: Flat urothelial lesions;Les tumeurs urothéliales dites «superficielles» de la vessie. Quelle classification en 2003? 2e partie: Les lésions planes

Annales de Pathologie

Volumn 23, Issue 1, 2003, Pages 35-45

  Sibony, Mathilde ^a   Billerey, Claude ^b  

^a HÔPITAL TENON   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Carcinoma in situ; Reactive urothelial atypia; Urinary bladder; Urothelial dysplasia; Urothelial metaplasia

Indexed keywords

BLADDER TUMOR; CANCER CLASSIFICATION; CARCINOGENESIS; CARCINOMA IN SITU; DYSPLASIA; FLAT UROTHELIAL LESION; HUMAN; HUMAN TISSUE; ITALY; PRECANCER; REVIEW; SUPERFICIAL BLADDER TUMOR; UROGENITAL TRACT TUMOR; BLADDER; CLASSIFICATION; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; PATHOLOGY; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

TUMOR MARKER;

CARCINOMA, TRANSITIONAL CELL; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0037712547     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22:1435-48.
2. Lopez-Beltran A, Cheng HL, Andersson L, Brausi M, de Matteis A, Montironi R et al. Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. Virchows Arch 2002; 440: 3-11.
3. Melicow M, Hollowell J. Intra-urothelial cancer: Carcinoma in situ, Bowen's disease of the urinary system: Discussion of 30 cases. J Urol 1952; 68: 763-71.
4. Koss LG. Tumors of the urinary bladder. Washington DC: Series S, 1975.
5. Nagy GK, Frable WJ, Murphy WM. Classification of premalignant urothelial abnormalities. A Delphi study of the National Bladder Cancer Collaborative Group A. Pathol Annu 1982; 17: 219-33.
6. Mostofi FK, Sesterhenn IA. Pathology of epithelial tumors and carcinoma in situ of bladder. Prog Clin Biol Res 1984; 55-74
7. Murphy WM, B. BJ and Farrow GM. Tumors of the kidney, bladder, and related urinary structures. Washington DC: Third edition, 1994.
8. Amin MB, Young RH. Intraepithelial lesions of the urinary bladder with a discussion of the histogenesis of urothelial neoplasia. Semin Diagn Pathol 1997; 14: 84-97.
9. Mostofi FK, Davis CJ. Histological typing of urinary bladder tumours. Geneva: Who, 1999.
10. Cox PJ. Cyclophosphamide cystitis - identification of acrolein as the causative agent. Biochem Pharmacol 1979; 28: 2045-9.
11. Murphy WM, Soloway MS, Finebaum PJ. Pathological changes associated with topical chemotherapy for superficial bladder cancer. J Urol 1981; 126: 461-4.
12. Lopez Beltran A. Bladder treatment. Immunotherapy and chemotherapy. Urol Clin North Am 1999; 26: 535-54
13. Murphy WM, Busch C, Algaba F. Intraepithelial lesions of the urinary bladder: morphologic considerations. Scand J Urol Nephrol 2000; Suppl 205: 67-81:
14. Cheng L, Cheville JC, Neumann RM, Bostwick DG. Flat intraepithelial lesions of the urinary bladder. Cancer 2000; 88: 625-31.
15. Helpap B, Kollermann J. Assessment of basal cell status and proliferative patterns in flat and papillary urothelial lesions: a contribution to the new WHO classification of the urothelial tumors of the urinary bladder. Hum Pathol 2000; 31: 745-50.
16. Koss LG. Mapping of the urinary bladder: its impact on the concepts of bladder cancer. Hum Pathol 1979; 10: 533-48.
17. Taylor DC, Bhagavan DS, Larsen MP. Papillary urothelial hyperplasia: a precursor to papillary neoplasm. Am J Surg Pathol 1996; 20: 1481-88
18. Benson RC, Swanson SK, Farrow GM. Relationship of leukoplakia to urothelial malignancy. J Urol 1984; 131: 507-11
19. Khafagy MM, El Bokainy MN, Mansour MA. Carcinoma of the bilharzial urinary bladder: a study of the associated mucosal lesions in 86 cases. Cancer 1972; 30: 150-59
20. Chan TY, Epstein JI. In situ adenocarcinoma of the bladder. Am J Surg Pathol 2001; 25: 892-99
21. Baud E, Catilina P, Boitux JP, Bignon YJ. Human bladder cancers and normal bladder mucosa present the same hot spot of heterozygous chromosome-9 deletion. Int J Cancer 1998; 77: 821-24
22. Baithun SI, Naase M, Blanes A, Diaz-Cano SJ. Molecular and kinetic features of transitional cell carcinomas of the bladder: biological and clinical implications. Virchows Arch 2001; 438: 289-97
23. Zuk RJ, Rogers HS, Martin JE, Baithun SI. Clinico-pathological importance of primary dysplasia of bladder. J Clin Pathol 1988; 41: 1277-80.
24. Cheng L, Cheville JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 1999; 23: 443-7.
25. Wolf H, Olsen PR, Fischer A, Hojgaard K. Urothelial atypia concomitant with primary bladder tumour. Incidence in a consecutive series of 500 unselected patients. Scand J Urol Nephrol 1987; 21: 33-8
26. Murphy WM, Soloway MS. Urothelial dysplasia. J Urol 1982; 127: 849-54.
27. Althausen AF, Prout GR, Jr., Daly JJ. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976; 116: 575-80.
28. Wolf H, Hojgaard K. Urothelial dysplasia in random mucosal biopsies from patients with bladder tumours. Scand J Urol Nephrol 1980; 14: 37-41
29. Smith G, et al. Prognostic significance of biopsy results of normal-looking mucosa in cases of superficial bladder cancer. Br J Urol 1983; 55: 665-9.
30. Billerey C, Le Pessot F. Classification histologique et facteurs pronostiques des cancers de la vessie et des voies excrétrices supérieures. Oncologie 2000; 2: 293-302
31. McKenney JK, Gomez JA, Desai S, Lee MW, Amin MB. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol 2001; 25: 356-62.
32. Orozco RE, Vander Zwaag R, Murphy WM. The pagetoid variant of urothelial carcinoma in situ. Hum Pathol 1993; 24: 1199-202.
33. Farrow GM. Pathology of carcinoma in situ of the urinary bladder and related lesions. J Cell Biochem Suppl 1992; 39-43
34. Orozco RE, Martin AA, Murphy WM. Carcinoma in situ of the urinary bladder. Clues to host involvement in human carcinogenesis. Cancer 1994; 74: 115-22.
35. Hudson MA, Herr HW. Carcinoma in situ of the bladder. J Urol 1995; 153: 564-72.
36. Cheng L, Cheville JC, Neumann RH, Leibovich BC, Egan KS, Spotts BE et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 1999; 85: 2469-74.
37. Billerey C, Sibony M, Gattegno B, Chopin D. Anatomie pathologique des tumeurs superficielles de la vessie. Prog Urol 2001; 11: 805-63
38. McKenney JK, Desai S, Cohen C, Amin MB. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p 53, and CD44 antigens. Am J Surg Pathol 2001; 25: 1074-8.
39. Cina SJ, Lancaster-Weiss KJ, Lecksell K, Epstein JI. Correlation of Ki-67 and p53 with the new World Health Organization/International Society of Urological Pathology Classification System for Urothelial Neoplasia. Arch Pathol Lab Med 2001; 125: 646-51.
40. Chopin D. p53 et pronostic des tumeurs urothéliales vésicales. Pathol Biol (Paris) 1997; 45: 893-7.
41. Endl E, Gerdes J. Posttranslational modifications of the KI-67 protein coincide with two major checkpoints during mitosis. J Cell Physiol 2000; 182: 371-80.
42. Guinebretiere JM, Sabourin JC. Ki-67, marqueur de prolifération. Ann Pathol 1997; 17: 25-30.
43. Harnden P, Eardley I, Joyce AD, Southgate J. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol 1996; 78: 870-5.
44. Soloway MS. The management of superficial bladder cancer. Cancer 1980; 45: 1856-65.